Program Overview

Over four days, internationally recognized experts will address topics including:

• Variant interpretation and genomic databases

• Risk prediction and polygenic risk scores

• Applied molecular genetics and homologous recombination deficiency

• Early detection through circulating tumour DNA and AI-assisted imaging

• Management of hereditary breast, ovarian and related cancers

• Population screening and whole genome sequencing

• Emerging therapies and precision medicine

• Artificial intelligence and future directions in hereditary cancer care

The program combines keynote lectures, proffered papers, poster presentations, roundtable discussions and highly interactive Special Interest Groups, creating valuable opportunities for learning, collaboration and scientific exchange.

Beyond the scientific symposium, BRCA 2027 also hosts a dedicated Public Conference that empowers patients, gene carriers, families and caregivers with the latest information on hereditary cancer, extending the event's impact beyond the scientific community.

BRCA 2027 will welcome an outstanding faculty of internationally recognized leaders in hereditary cancer research and clinical care. Representing many of the world's foremost academic institutions and cancer centres across North America and Europe, these experts will share the latest advances in genetics, precision medicine, screening, prevention and patient management.

Stay tuned for more information on our invited speakers.